Rosiglitazone inhibits angiotensin II-induced C-reactive protein production in human aortic endothelial cells through regulating AT1-ROS-MAPK signal pathway

Inflammation Research

Volumn 61, Issue 9, 2012, Pages 1031-1037

  Han, Chun Jie ^a,b   Liu, Jun Tian ^a   Li, Ming ^a   Cui, Mu ^c   Pang, Xiao Ming ^a   Mao, Jun Jun ^a   Liu, Xiao Fang ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b Shaanxi Institute for Food and Drug Control   (China)

^c XI'AN MEDICAL UNIVERSITY   (China)

Author keywords

Angiotensin II; C reactive protein; Endothelial cells; Inflammation; Rosiglitazone

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; C REACTIVE PROTEIN; LOSARTAN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; STRESS ACTIVATED PROTEIN KINASE;

AORTA; ARTERY ENDOTHELIUM; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; ENZYME REGULATION; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; INCUBATION TIME; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANGIOTENSIN I; ANGIOTENSIN II; ANTI-INFLAMMATORY AGENTS; AORTA; C-REACTIVE PROTEIN; CELLS, CULTURED; ENDOTHELIAL CELLS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PPAR GAMMA; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; THIAZOLIDINEDIONES;

EID: 84865108427     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-012-0496-9     Document Type: Article

References (35)

1. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2001;105:1135-43. (Pubitemid 34212626)
2. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension. 2004;44:6-11. (Pubitemid 38823477)
3. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363-9. (Pubitemid 36158034)
4. Kibayashi E, Urakaze M, Kobashi C, Kishida M, Takata M, Sato A, Yamazaki K, et al. Inhibitory effect of pitavastatin (NK-104) on the C-reactive-protein- induced interleukin-8 production in human aortic endothelial cells. Clin Sci. 2005;108:515-21. (Pubitemid 40827559)
5. Li L, Roumeliotis N, Sawamura T, Renier G. C-reactive protein enhances LOX-1 expression in human aortic endothelial cells: relevance of LOX-1 to C-reactive protein-induced endothelial dysfunction. Circ Res. 2004;95:877-83. (Pubitemid 39435002)
6. Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation. 2001;103:2531-4. (Pubitemid 32521959)
7. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation. 2001;106:1439-41.
8. Venugopal SK, Devaraj S, Jialal I. C-reactive protein decreases prostacyclin release from human aortic endothelial cells. Circulation. 2003;108:1676-8. (Pubitemid 37243652)
9. Calabro P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation. 2003;108:1930-2. (Pubitemid 37296536)
10. Singh P, Hoffmann M, Wolk R, Shamsuzzaman AS, Somers VK. Leptin induces C-reactive protein expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2007;27:E302-7. (Pubitemid 47312298)
11. Venugopal SK, Devaraj S, Jialal I. Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects. Am J Pathol. 2005;166:1265-71. (Pubitemid 40524449)
12. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol. 2001;158:1039-51. (Pubitemid 32221796)
13. Han C, Liu J, Liu X, Li M. Angiotensin II induces C-reactive protein expression through ERK1/2 and JNK signaling in human aortic endothelial cells. Atherosclerosis. 2010;212:206-12.
14. Lee CH, Olson P, Evans RM. Lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology. 2003;144:2201-7. (Pubitemid 36629867)
15. Yano Y, Hoshide S, Ishikawa J, Noguchi C, Tukui D, Takanori H, Tada M, et al. The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients. Am J Hypertens. 2007;20:565-72. (Pubitemid 46691290)
16. Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J. PPAR gamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPAR gamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol. 1999;19:546-51. (Pubitemid 29135154)
17. Gao DF, Niu XL, Hao GH, Peng N, Wei J, Ning N, Wei J, et al. Rosiglitazone inhibits angiotensin II-induced CTGF expression in vascular smooth muscle cells-role of PPAR-gamma in vascular fibrosis. Biochem Pharmacol. 2007;73:185-97. (Pubitemid 44855720)
18. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391:79-82. (Pubitemid 28079218)
19. Abdelrahman M, Sivarajah A, Thiemermann C. Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc Res. 2005;65:772-81. (Pubitemid 40249723)
20. Goetze S, Xi XP, Graf K, Fleck E, Hsueh WA, Law RE. Troglitazone inhibits angiotensin II-induced extracellular signalregulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells. FEBS Lett. 1999;452:277-82. (Pubitemid 29301760)
21. Ishibashi M, Egashira K, Hiasa K, Inoue S, Ni WH, Zhao QW, Usui M, et al. Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension. 2002;40:687-93. (Pubitemid 35282444)
22. Ryan MJ, Didion SP, Mathur S, Faraci FM, Sigmund CD. PPAR (gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension. 2004;43:661-6. (Pubitemid 38282444)
23. Wang TD, Chen WJ, Lin JW, Chen MF, Lee YT. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol. 2004;93:362-5.
24. Parinandi NL, Kleinberg MA, Usatyuk PV, Cummings RJ, Pennathur A, Cardounel AJ, Zweier JL, et al. Hyperoxia-induced NAD(P)H oxidase activation and regulation by MAP kinases in human lung endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2003;284:L26-38. (Pubitemid 35471255)
25. Ayabe N, Babaev VR, Tang Y, Tanizawa T, Fogo AB, Linton MF, Ichikawaa I, et al. Transiently heightened angiotensin II has distinct effects on atherosclerosis and aneurysm formation in hyperlipidemic mice. Atherosclerosis. 2006;184:312-21. (Pubitemid 43049715)
26. da Cunha V, Tham DM, Martin-McNulty B, Deng G, Ho JJ, Wilson DW, Rutledge JC, et al. Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. Atherosclerosis. 2005;178:9-17. (Pubitemid 39600810)
27. Kumar HAS, Ramarao P. Saga of renin-angiotensin system and calcium channels in hypertensive diabetics: does it have a therapeutic edge? Cardiovasc Drug Rev. 2005;23:99-114. (Pubitemid 41278970)
28. Min Q, Bai YT, Jia G, Wu J, Xiang JZ. High glucose enhances angiotensin-II-mediated peroxisome proliferation-activated receptor-gamma inactivation in human coronary artery endothelial cells. Exp Mol Pathol. 2010;88:133-7.
29. Takeda K, Ichiki T, Tokunou T, Funakoshi Y, Iino N, Hirano K, Kanaide H, et al. Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation. 2000;102:1834-9.
30. Nisbet RE, Bland JM, Kleinhenz DJ, Mitchell PO, Walp ER, Sutliff RL, Hart CM. Rosiglitazone attenuates chronic hypoxiainduced pulmonary hypertension in a mouse model. Am J Resp Cell Mol Biol. 2010;42:482-90.
31. Schiffrin EL. Peroxisome proliferator-activated receptors and cardiovascular remodeling. Am J Physiol Heart Circ Physiol. 2005;288:H1037-43. (Pubitemid 40270004)
32. Chan SHH, Hsu KS, Huang CC, Wang LL, Ou CC, Chan JYH. NADPH oxidase-derived superoxide anion mediates angiotensin II-induced pressor effect via activation of p38 mitogen-activated protein kinase in the rostral ventrolateral medulla. Circ Res. 2005;97:772-80. (Pubitemid 41447127)
33. Ji Y, Liu J, Wang Z, Liu N, Gou W. PPAR gamma agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway. Lab Invest. 2009;89:887-902.
34. Hsu YH, Chen JJ, Chang NC, Chen CH, Liu JC, Chen TH, Jeng CJ, et al. Role of reactive oxygen species-sensitive extracellular signal-regulated kinase pathway in angiotensin-II-induced endothelin- 1 gene expression in vascular endothelial cells. J Vasc Res. 2004;41:64-74.
35. Orasanu G, Ziouzenkova O, Devchand RP, Nehra V, Hamdy O, Horton SE, Plutzky J. The peroxisome proliferators-activated receptor-c agonist pioglitazone represses inflammation in a peroxisome proliferators-activated receptor-a dependent manner in vitro and in vivo in mice. J Am Coll Cardiol. 2008;52:869-81.